Skip to main content
Clinical Trials/NCT04908943
NCT04908943
Completed
Not Applicable

RENEW Scleroderma: A Peer-Mentored, Web Intervention for Resilience-based, Energy Management to Enhance Wellbeing and Fatigue

University of Michigan1 site in 1 country174 target enrollmentAugust 28, 2021
ConditionsScleroderma

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Scleroderma
Sponsor
University of Michigan
Enrollment
174
Locations
1
Primary Endpoint
Change in Fatigue
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

The researchers seek to understand if the Resilience-based, Energy Management to Enhance Wellbeing and Fatigue (RENEW) program helps with scleroderma symptom management and disease burden. The researchers think that those participants who receive the intervention will have clinically meaningful changes of symptom management and disease burden.

Registry
clinicaltrials.gov
Start Date
August 28, 2021
End Date
May 29, 2023
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Susan Murphy

Professor of Physical Medicine and Rehabilitation and Research

University of Michigan

Eligibility Criteria

Inclusion Criteria

  • Have a diagnosis of Systemic Sclerosis (SSc), any subtype
  • Report a mean score of at least 4 on the Fatigue Severity Scale; potential mean range 1-9
  • Have access to a computer and an internet connection
  • Are able to speak and read English.

Exclusion Criteria

  • Currently undergoing structured rehabilitation or psychological treatment.
  • Other issues that preclude meaningful participation in study procedures (e.g. concurrent or complex medical issues, inability to access RENEW intervention, etc.)

Outcomes

Primary Outcomes

Change in Fatigue

Time Frame: Up to 12 weeks

Fatigue is measured by The Functional Assessment of Chronic Illness Therapy (FACIT) -Fatigue 13a. FACIT is a questionnaire with 13 questions and a score ranging from 13-65. Higher scores indicate greater fatigue.

Secondary Outcomes

  • Change in Pain Interference(Up to 12 weeks)
  • Change in Resilience(Up to 12 weeks)
  • Change in Depressive symptoms(Up to 12 weeks)

Study Sites (1)

Loading locations...

Similar Trials